Beyond the Scale” focuses on obesity as a chronic disease — urging empathy, early intervention, and evidence-based ...

In the race to make the most tolerable obesity drug, there seems to be no clear winner—at least not according to analysts ...

SINGAPORE - Media OutReach Newswire - 27 June 2025 -Imagine a chronic disease affecting more than 600,000 people 1-3 in Singapore — yet often misunderstood, overlooked, or surrounded by stigma. This ...

Shares in biopharmaceutical company Viking Therapeutics (NASDAQ: VKTX) were up by 6.3% at 12:30 a.m. ET today. The move ...

Earlier this week, the pharma giant publicly accused Hims & Hers of “deceptive” marketing that is putting patient safety at risk.

Combination therapy with a long-acting amylin analogue and a glucagon-like peptide-1 (GLP-1) receptor agonist results in ...

Uninsured or self-pay obesity patients can get any dose of Wegovy for $299 from July 1–31, 2025. Patients can get their ...

A Fierce Pharma Marketing review of the LinkedIn and Instagram pages of the 20 largest pharmas found that, as of Thursday, ...

Novo Nordisk continues to expand its partnerships with telehealth companies to broaden access to its blockbuster weight loss ...

Novo Nordisk said on Thursday it will collaborate with WeightWatchers to sell its blockbuster weight-loss drug Wegovy, ...

A new study says common human typing errors can trip up artificial intelligence (AI) programs designed to aid health care ...

Novo Nordisk plans to expand access to Wegovy through a collaboration with WeightWatchers, days after ending a partnership with telehealth firm Hims & Hers to sell the weight-loss drug.